
Opinion|Videos|February 9, 2026
Utilizing NCCN Guidelines for Treatment Guidance in EGFR-Mutated NSCLC
Author(s)Narjust Florez, MD
New subcutaneous amivantamab cuts infusion reactions and steroid burden, reduces clinic visits, and shows improved outcomes in PALOMA-3.
Advertisement
Episodes in this series

Narjust Florez, MD, explains how the National Comprehensive Cancer Network (NCCN) Guidelines inform evidence-based treatment selection in EGFR-mutated advanced non–small cell lung cancer (NSCLC). Florez describes how guideline recommendations integrate clinical trial data, molecular testing results, and line-of-therapy considerations. She underscores the role of guidelines as a framework that must still be adapted to individual patient characteristics and real-world clinical complexity.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

